Genmab A/S Share Price Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
01:30:00 24/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 34.75 USD | -1.33% |
|
+1.02% | +12.82% |
| 10:37am | Hansa Biopharma brings in two new board members | FW |
| 10:25am | Nordic stocks in North America, Astra Zeneca fell 1.2% | FW |
| Market Cap | 14TCr 2.09TCr 1.83TCr 1.72TCr 1.57TCr 2.94TCr 1,99900Cr 2.96TCr 21TCr 8.02TCr 1,01900Cr 7.84TCr 7.67TCr 3,30500Cr | P/E 2026 * |
28.6x | P/E 2027 * | 20.6x |
|---|---|---|---|---|---|
| Enterprise Value | 16TCr 2.38TCr 2.09TCr 1.96TCr 1.79TCr 3.35TCr 2,27900Cr 3.38TCr 24TCr 9.14TCr 1,16200Cr 8.93TCr 8.74TCr 3,76700Cr | EV / Sales 2026 * |
5.38x | EV / Sales 2027 * | 4.4x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GMAB | Delayed | |
CBOE
| GMAB | Real-time | |
|
Börse Stuttgart
| GE91 | Delayed | |
|
Tradegate
| GE91 | Real-time | |
|
Deutsche Boerse AG
| GE91 | Delayed | |
|
Boerse Muenchen
| GE91 | Real-time |
Last Transcript: Genmab A/S
| 1 day | -1.33% | ||
| 1 week | +1.02% | ||
| Current month | +4.79% | ||
| 1 month | +3.89% | ||
| 3 months | +33.96% | ||
| 6 months | +35.32% | ||
| Current year | +12.82% |
| 1 week | 34.36 |  | 35.66 |
| 1 month | 32.21 | | 35.66 |
| Current year | 23.62 | | 35.66 |
| 1 year | 23.62 | | 35.66 |
| 3 years | 17.24 | | 36.71 |
| 5 years | 17.24 | | 47.5 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.33% | +1.02% | - | - | 2.09TCr | |
| +0.06% | +6.49% | +60.29% | +111.13% | 7.42TCr | |
| +0.19% | -3.57% | +34.57% | +75.40% | 5.96TCr | |
| -2.05% | -3.46% | -18.60% | +352.20% | 2.58TCr | |
| -2.39% | +2.74% | +0.19% | -5.91% | 2.47TCr | |
| -0.94% | +1.07% | +21.45% | -10.04% | 2.09TCr | |
| +1.29% | -2.49% | +152.11% | +333.06% | 1.53TCr | |
| -2.44% | -0.09% | +42.50% | +164.11% | 1.41TCr | |
| -3.91% | -4.91% | -14.10% | +779.68% | 1.31TCr | |
| -1.12% | -3.04% | +15.72% | +234.56% | 1.19TCr | |
| Average | -1.27% | -0.40% | +32.68% | +226.02% | 2.88TCr | |
| Weighted average by Cap. | -0.81% | +0.70% | +36.34% | +161.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.9TCr 441.81Cr 387.77Cr 364.51Cr 333.26Cr 622.74Cr 42TCr 627.36Cr 4.38TCr 1.7TCr 22TCr 1.66TCr 1.62TCr 70TCr | 3.36TCr 512.69Cr 449.99Cr 422.99Cr 386.72Cr 722.65Cr 49TCr 728.02Cr 5.08TCr 1.97TCr 25TCr 1.93TCr 1.88TCr 81TCr |
| Net income | 497.31Cr 76Cr 67Cr 63Cr 57Cr 106.81Cr 7.26TCr 107.61Cr 750.97Cr 291.13Cr 3.7TCr 284.57Cr 278.34Cr 12TCr | 709.44Cr 108.1Cr 95Cr 89Cr 82Cr 152.38Cr 10TCr 153.51Cr 1.07TCr 415.31Cr 5.28TCr 405.96Cr 397.06Cr 17TCr |
| Net Debt | 1.92TCr 292.15Cr 256.42Cr 241.03Cr 220.37Cr 411.8Cr 28TCr 414.85Cr 2.9TCr 1.12TCr 14TCr 1.1TCr 1.07TCr 46TCr | 1.1TCr 168.16Cr 147.59Cr 138.74Cr 126.84Cr 237.02Cr 16TCr 238.78Cr 1.67TCr 646.03Cr 8.21TCr 631.48Cr 617.64Cr 27TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | $34.75 | -1.33% | 25,09,746 |
| 22/26/22 | $35.22 | +1.53% | 22,97,611 |
| 21/26/21 | $34.69 | -0.14% | 15,77,461 |
| 18/26/18 | $34.74 | +0.59% | 27,11,562 |
| 17/26/17 | $34.54 | +0.39% | 27,03,043 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
